Biosimilar breast cancer drug trial ends early
NCT ID NCT06038539
First seen Mar 18, 2026 · Last updated Apr 25, 2026 · Updated 4 times
Summary
This study tested a new biosimilar drug (PERT-IJS) against the approved drug Perjeta for people with a certain type of breast cancer (HER2-positive, hormone receptor-negative) that had not spread far. The goal was to see if the biosimilar worked as well at shrinking tumors before surgery. The trial was stopped early and included 55 women.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR NEGATIVE HER2 POSITIVE EARLY BREAST CANCER OR LOCALLY ADVANCED BREAST CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chopda Medicare & Research Centre Pvt. Ltd,
Nashik, 422005, India
Conditions
Explore the condition pages connected to this study.